BOSTON (AP) — General Electric is selling its biopharma business to Danaher Corp. for $21.4 billion as it continues to sell off chunks of a once sprawling conglomerate.
The biopharma unit, part of GE Life Sciences, generated revenue of about $3 billion last year. Danaher said after tax benefits, the deal will have a price tag that is closer a $20 billion. The mostly-cash transaction is expected to close in the fourth quarter of this year.
Danaher, a medical technology company based in Washington, D.C., said GE's biopharma segment will operate as a separate company within Danaher's $6.5 billion Life Sciences division.
GE has shrunk considerably since becoming entangled in the financial crisis a decade ago and is seeking to divest even more of its businesses. Last fall, GE sold part of its Healthcare Equipment Finance business to TIAA Bank and agreed to sell its Current, powered by GE business — part of the company's lighting business — to American Industrial Partners.
In October, the company slashed its quarterly dividend and announced it was restructuring its power business shortly after ousting CEO John Flannery after only about a year on the job. After being named as the new CEO, Larry Culp said GE needed to simplify its business structure even more.
GE said this month that it would downsize its world headquarters in Boston and return $87 million in incentives it received from Massachusetts for moving from Connecticut three years ago.
It also dropped plans to build a 12-story office tower on the city's waterfront that was to be the centerpiece of its new global headquarters. It will sell that parcel of land along with two older, state-owned buildings that were being refurbished for the company.
Despite ongoing struggles in its power division, GE posted better-than-expected revenue last quarter on the strength of its other business segments.
Shares of GE jumped nearly 17 percent before the opening bell Monday. The company's shares have risen about 34 percent since the beginning of the year, but are still down almost 30 percent from a year ago.
Before you consider Danaher, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Danaher wasn't on the list.
While Danaher currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
